Skip to Main Content
Contribute Try STAT+ Today

Although the pharmaceutical industry is making modest progress in countering resistance to superbugs, drug companies are not doing enough to ensure greater access to lifesaving antibiotics in low and middle-income countries, a new analysis finds.

Just one-third of 166 treatments assessed have any kind of access strategy in place, such as price adjustments to make antibiotics more affordable or licensing agreements to boost supplies for these countries, according to the report by the Access to Medicines Foundation, an independent, not-for-profit research organization that evaluates drug makers on how they ensure access to medicines.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment